Changeflow GovPing Pharma & Drug Safety Liquid Composition Comprising Protein Patent Gr...
Routine Rule Added Final

Liquid Composition Comprising Protein Patent Granted

Favicon for changeflow.com ChangeBridge: Patent Grants - Pharma (A61K)
Published
Detected
Email

Summary

The USPTO granted Patent US12594322B2 to Samsung Bioepis Co., Ltd. on April 7, 2026, covering a protein-stabilized liquid formulation composition. The patent includes a stabilizer and surfactant without buffer components, a protein liquid composition using this stabilization method, and a production method. The patent contains 12 claims and was filed on September 10, 2019.

What changed

USPTO issued Patent US12594322B2 to Samsung Bioepis Co., Ltd. for a liquid composition comprising protein with a stabilizer and surfactant system that excludes buffers. The patent covers the composition for protein stabilization, the protein liquid composition incorporating the stabilization composition, and the method of producing the stabilized composition. The patent contains 12 claims across pharmaceutical formulation technology.

Affected parties include Samsung Bioepis competitors developing protein-based liquid pharmaceuticals, who must now account for this patent estate in their product development and freedom-to-operate analyses. Generic and biosimilar manufacturers targeting similar formulation technologies may need to design around these claims or seek licensing arrangements with Samsung Bioepis.

What to do next

  1. Monitor for updates

Archived snapshot

Apr 7, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Grants

Liquid composition comprising protein

Grant US12594322B2 Kind: B2 Apr 07, 2026

Assignee

SAMSUNG BIOEPIS CO., LTD.

Inventors

Inae Kim, Soyun Jung, Jaemin Lee, Hun Joo Lee, Yongkook Kim

Abstract

The present invention relates to a protein-stabilized liquid formulation and provides: a composition for protein stabilization, the composition including a stabilizer and a surfactant and not including a buffer; a protein liquid composition including the composition for stabilization and a protein; and a method of producing a protein-stabilized liquid composition which uses the composition for stabilization.

CPC Classifications

A61K 47/26 A61K 47/10 A61K 9/08

Filing Date

2019-09-10

Application No.

17274834

Claims

12

View original document →

Get daily alerts for ChangeBridge: Patent Grants - Pharma (A61K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.

Last updated

Classification

Agency
USPTO
Published
April 7th, 2026
Instrument
Rule
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
US12594322B2

Who this affects

Applies to
Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent prosecution IP licensing Product formulation
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals

Get alerts for this source

We'll email you when ChangeBridge: Patent Grants - Pharma (A61K) publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.